Ketanserin: a novel cardiovascular drug
- PMID: 2130934
Ketanserin: a novel cardiovascular drug
Abstract
Ketanserin is the archetype of a new class of cardiovascular drugs, the 5HT2 (S2) serotonergic receptor antagonists. In humans, ketanserin inhibits serotonin-induced vasoconstriction and platelet activation. In addition, it reduces platelet hyperactivity, blood viscosity and total serum cholesterol. The antihypertensive effect of ketanserin is more pronounced in older people, in whom it decreases blood pressure gradually to normal levels. It lowers systemic vascular resistance resulting in a reduction of pre- and afterload. It improves vascular compliance and reduces left ventricular hypertrophy. Ketanserin improves the microcirculation of the skin, in particular capillary blood flow. Placebo-controlled studies have established that ketanserin prevents amputations in patients with atherosclerosis, enhances ulcer healing in patients with scleroderma and reduces the frequency and duration of attacks in patients with Raynaud's disease. In a placebo-controlled trial the on-treatment analysis of 3071 patients with intermittent claudication (the PACK-trial) showed a 23% reduction of severe cardiovascular events with ketanserin, suggesting that ketanserin may prevent complications of atherosclerosis. The accumulated clinical evidence indicates that serotonergic antagonism opens new perspectives in the treatment of cardiovascular disease. Current clinical research with ketanserin further explores its potential as a vascular protective agent.
Similar articles
-
Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.Int Angiol. 1988 Jan-Mar;7(1):19-25. Int Angiol. 1988. PMID: 3290356 Clinical Trial.
-
Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.J Cardiovasc Pharmacol. 1987;10 Suppl 3:S26-31. J Cardiovasc Pharmacol. 1987. PMID: 2446064 Clinical Trial.
-
Effect of ketanserin in the treatment of patients with intermittent claudication: results from 13 placebo-controlled parallel group studies.J Cardiovasc Pharmacol. 1987;10 Suppl 3:S89-95. J Cardiovasc Pharmacol. 1987. PMID: 2446082 Clinical Trial.
-
Age-related effects of 5-HT2 antagonists.J Cardiovasc Pharmacol. 1991;17 Suppl 5:S29-34. J Cardiovasc Pharmacol. 1991. PMID: 1717770 Review.
-
Age and 5HT 2-receptor blockade with ketanserin in essential hypertension.Rev Port Cardiol. 1989 Sep;8(9):621-4. Rev Port Cardiol. 1989. PMID: 2698721 Review.
Cited by
-
Immunohistochemical Evaluation of Role of Serotonin in Pathogenesis of Psoriasis.J Clin Diagn Res. 2016 Oct;10(10):EC05-EC09. doi: 10.7860/JCDR/2016/22692.8719. Epub 2016 Oct 1. J Clin Diagn Res. 2016. PMID: 27891342 Free PMC article.
-
Melatonin increases the regularity of cardiac rhythmicity in the Drosophila heart in both wild-type and strains bearing pathogenic mutations.J Comp Physiol B. 2017 Jan;187(1):63-78. doi: 10.1007/s00360-016-1019-8. Epub 2016 Jul 22. J Comp Physiol B. 2017. PMID: 27448293
-
Effects of ketanserin on hypergranulation tissue formation, infection, and healing of equine lower limb wounds.Can Vet J. 2004 Feb;45(2):144-9. Can Vet J. 2004. PMID: 15025151 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources